Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-009 Phase Ib in T2DM
NCT04345107Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of yagratide in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum postprandial blood glucose added value at 7 days, Blood glucose Area Under Curve at 7 days and 5 more. Started May 2020; status: completed.
02
Drugs
yagratide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04345107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345107.